

The following Listing of the Claims will replace all prior versions and all prior listings:

Listing of The Claims:

1. (Currently amended) A method for treating a solid cancerous tumor, which comprises administering to a mammal in need of such treatment an effective amount of DMXAA or a pharmaceutically acceptable salt or ester thereof and administering an effective amount of gemcitabine ~~at least one of a compound selected from platinum compounds, vinca alkaloids, cyclophosphamide, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors.~~
2. (Currently amended) A method for treating a solid cancerous tumor, which comprises administering to a mammal in need of such treatment an effective amount of DMXAA or a pharmaceutically acceptable salt or ester thereof and administering an effective amount of gemcitabine ~~at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, wherein the DMXAA or pharmaceutically acceptable salt or ester thereof and the at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors are administered in a potentiating ratio.~~
3. (Currently amended) A The method according to claim 1 or claim 2, wherein the DMXAA or pharmaceutically acceptable salt or ester thereof and the gemcitabine ~~the at least one of a compound selected from platinum compounds, vinca alkaloids, cyclophosphamide, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors~~ are administered concomitantly.
4. (Currently amended) A method for treating a solid cancerous tumor, which comprises administering to a mammal in need of such treatment an effective amount of DMXAA or a pharmaceutically acceptable salt or ester thereof and administering an effective amount of gemcitabine ~~at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, wherein the DMXAA or pharmaceutically acceptable salt or ester thereof and the gemcitabine at least one of a compound selected from~~

~~platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors~~ are administered sequentially.

5. (Cancel)
6. (Cancel)
7. (Currently amended) A composition comprising a combination of DMXAA or a pharmaceutically acceptable salt or ester thereof and gemcitabine ~~at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors~~.
8. (Currently amended) ~~A~~ The composition according to claim 7 wherein the DMXAA or a pharmaceutically acceptable salt or ester thereof and the gemcitabine ~~the at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors~~ are present in a potentiating ratio.
9. (Cancel)
10. (Cancel)
11. (Currently amended) A pharmaceutical formulation comprising a combination of DMXAA or a pharmaceutically acceptable salt or ester thereof and gemcitabine ~~at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors~~ in association with one or more pharmaceutically acceptable carriers therefor.
12. (Original) A pharmaceutical formulation according to claim 11 wherein the formulation is adapted for intravenous administration.
13. (Currently amended) ~~A~~ The pharmaceutical formulation according to claim 11 or 12 wherein the DMXAA or pharmaceutically acceptable salt or ester thereof and the gemcitabine ~~the at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors~~ are present in a potentiating ratio.

14. (Cancel)
15. (Cancel)
16. (Currently amended) A process for the preparation of a pharmaceutical formulation which process comprises bringing into association a combination of DMXAA or a pharmaceutically acceptable salt or ester thereof and gemcitabine at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors with one or more pharmaceutically acceptable carriers therefor.
17. (Currently amended) A The process according to claim 16 wherein the DMXAA or pharmaceutically acceptable salt or ester thereof and the gemcitabine the at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors are present in a potentiating ratio.
18. (cancel)
19. (cancel)
20. (Currently amended) A kit comprising in association for separate administration DMXAA or a pharmaceutically acceptable salt or ester thereof and gemcitabine at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors.
21. (Currently amended) A The kit according to claim 20 wherein the DMXAA or pharmaceutically acceptable salt or ester thereof and gemcitabine the at least one of a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors are present in a potentiating ratio.
22. (Cancel)
23. (Cancel)
24. (Cancel)

25. (Cancel)

26. (Cancel)

27. (Cancel)